Encouraging data in advanced melanoma
There was a lot of great news from the ESMO Congress 2019 in Barcelona for melanoma patients. Written by Esther Drain.
There was a lot of great news from the ESMO Congress 2019 in Barcelona for melanoma patients. Written by Esther Drain.
BOSTON – Patients significantly overestimate the anticipated amount of pain they’ll experience following surgery, which researchers say can cause unnecessary anxiety in patients, according to a study being… read more.
The genetic and clinical heterogeneity of IBD means translational research has a key role to play. A session dedicated to translational and basic science at UEG Week 2019… read more.
An oral abstract session dedicated to patient-reported outcomes (PROs) in IBD included surveys from France and the Netherlands and from the multi-centre ICONIC study.. Written by Maria Dalby
Dr Maria Abreu (Miami, USA) gives us an overview of implementing disease monitoring and its challenges in clinical practice Written by Maria Dalby
A subcutaneous formulation of infliximab, known as CT-P13 SC, has been developed with a view to offer greater flexibility and convenience for patients.
In a round-up of randomised controlled studies in IBD at UEG Week 2019 included results from the maintenance phase of the UNIFI study in UC and a phase-3… read more.
Professor Jean-Frédéric Colombel (Icahn School of Medicine at Mount Sinai, New York, USA) opened the symposium with an overview of how treatment targets in UC have evolved from improving… read more.
UEGW 2019, held in Barcelona, Spain, was a very interesting meeting, covering a wide range of hot topics from the world on IBD. The meeting was well-attended with… read more.
Developing CAR-T cells that are effective in solid tumours is challenging but experience in Hodgkin Lymphoma could pave the way for CAR-T cells in lung cancer. Bi-specific T-cell… read more.
Tumours use a variety of mechanisms to escape the host immune system and overcoming these to increase response rates and improve quality of life are key goals. Manipulation… read more.
Targeted treatments for mutation-driven non-small cell lung cancer have advanced considerably but many questions remain about how to use these drugs to the best advantage and how to… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.